Penumbra, Inc.
NYQ: PENLive Quote
📈 ZcoreAI Score
Our AI model analyzes Penumbra, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PEN Z-Score →About Penumbra, Inc.
Healthcare
Medical Devices
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
📊 Fundamental Analysis
Penumbra, Inc. demonstrates a healthy profit margin of 12.7%.
The company recently reported 22.1% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 13.8%, which suggests room for improvement in capital utilization.
At a current price of $329.77, PEN currently sits at the 77th percentile of its 52-week range (Range: $221.26 - $362.41).
💰 Valuation Insight
PEN trades at a 191.8% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$12.94B
Trailing P/E
72.96
Forward P/E
51.67
Beta (5Y)
0.84
52W High
$362.41
52W Low
$221.26
Avg Volume
1.03M
Day High
Day Low